Monitor PALISADE-4 topline results in Q2 2026 as the key binary catalyst. The ICH E1 milestone is a necessary but not sufficient step toward an NDA, FDA alignment on safety database requirements remains unresolved. The stock's $21M market cap implies binary risk around the Phase 3 readout.
VTGN drugs
VTGN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 10 $0.5351entry
- T+1 · 5mo ago +7.10%α +5.40% · $0.5731
- T+5 · 5mo ago +28.95%α +25.52% · $0.6900
- T+20 · 4mo ago −53.43%α −57.05% · $0.2492
- T+60 · 2mo ago −53.99%α −60.57% · $0.2462
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure recommendations, with over 1,500 subjects receiving at least one dose, over 300 with at least 6 months of exposure, and over 100 with at least 12 months. This is a regulatory milestone for the NDA pathway, but the company has not yet aligned with the FDA on specific requirements. Topline results from the pivotal PALISADE-4 Phase 3 trial are expected in Q2 2026, and from the Phase 2 repeat dose study in Q3 2026.
Key Facts
- Fasedienol program exceeded ICH E1 minimum safety exposure recommendations as of May 31, 2026
- Over 1,500 subjects received at least a single exposure to fasedienol
- Over 300 subjects with at least 6 months of exposure
- Over 100 subjects with at least 12 months of exposure
- Vistagen has not yet aligned with the FDA on specific patient exposure requirements for an NDA
- Topline results from PALISADE-4 Phase 3 trial expected in Q2 2026
- Topline results from Phase 2 Repeat Dose study expected in Q3 2026
- Fasedienol has FDA Fast Track designation for acute treatment of social anxiety disorder
Financial Impact
No financial figures disclosed; milestone is regulatory/clinical, not financial
Risk Factors
- FDA has not yet agreed that the safety database is sufficient for NDA submission
- PALISADE-4 may fail to replicate PALISADE-2 positive results
- Company may need additional financing to complete development and regulatory submission
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-041962 |
| Document: vtgnex99106092026.htm | 0001628280-26-041962 |
| Document: 0001628280-26-041962-index-headers.html | 0001628280-26-041962 |
| Document: 0001628280-26-041962-index.html | 0001628280-26-041962 |
| Document: 0001628280-26-041962.txt | 0001628280-26-041962 |
Track record
21 reports on VTGN
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers